Update on Immune Mechanisms Associated with Sublingual Immunotherapy: Practical Implications for the Clinician

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 3, 2013, Pages 228-241

  Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

Author keywords

Allergen; Biomarker; Mucosal immunity; Regulatory T cell; Sublingual immunotherapy; Tolerance

Indexed keywords

ADENYLATE CYCLASE; ALLERGEN; CALCITRIOL; CD27 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CHITOSAN; DEXAMETHASONE; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 5; MALTODEXTRIN; PLACEBO; PROBIOTIC AGENT;

ALLERGY; ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CELL COUNT; CERVICAL LYMPH NODE; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EAR PRURITUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LANGERHANS CELL; LYMPHATIC DRAINAGE; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MAST CELL; MEDICAL DECISION MAKING; MEMORY T LYMPHOCYTE; MOUTH; MYELOID DENDRITIC CELL; NONHUMAN; ORAL PRURITUS; PATIENT SELECTION; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; RHINOPHARYNGITIS; SENSITIZATION; SIGNAL TRANSDUCTION; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SUBMUCOSA; TH1 CELL; THROAT IRRITATION; TONGUE EDEMA; TONSIL;

ALLERGEN; BIOMARKER; MUCOSAL IMMUNITY; REGULATORY T CELL; SUBLINGUAL IMMUNOTHERAPY; TOLERANCE;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNE TOLERANCE; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL IMMUNOTHERAPY;

EID: 84877045546     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.03.013     Document Type: Article

References (125)

1. Akdis M., Verhagen A., Taylor F., Karamloo F., Karagiannidis C., Crameri R., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004, 199:1567-1575.
2. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006, 61:151-165.
3. O'Hehir R.E., Sandrini A., Anderson G.P., Rolland J.M. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation. Curr Med Chem 2007, 14:2235-2244.
4. Scadding G., Durham S. Mechanisms of sublingual immunotherapy. J Asthma 2009, 46:322-334.
5. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011, 127:18-27.
6. Bahceciler N.N., Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know?. Curr Opin Allergy Clin Immunol 2012, 12:640-647.
7. Van Overtvelt L., Wambre E., Maillere B., von Hofe E., Louise A., Balazuc A.M., et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC Class II peptide tetramers. J Immunol 2008, 180:4514-4522.
8. Wilson D.R., Torres Lima M., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60:4-12.
9. Durham S.R., Yang W.H., Pederson M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802-809.
10. Didier A., Malling H.J., Worm M., Horak F., Jager S., Montagut A., et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338-1345.
11. Dahl R., Kapp A., Colombo G., de Monchy J.G.R., Rak S., Emminger W., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008, 121:512-518.
12. Durham S.R. Sublingual immunotherapy: what have we learnt from the "big trials" ?. Curr Opin Allergy Clin Immunol 2008, 8:577-584.
13. Passalacqua G., Durham S.R. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007, 119:881-891.
14. Canonica G.W., Bousquet J., Casale T., Lockey R.F., Baena-Cagnani C.E., Pawankar R., et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper. Allergy 2009, 64(Suppl 91):1-59.
15. Radulovic S., Wilson D., Calderon M., Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011, 66:740-752.
16. Cox L., Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009, 103:451-460.
17. Park I.H., Hong S.M., Lee H.M. Efficacy and safety of sublingual immunotherapy in Asian children. Int J Pediatr Otorhinolaryngol 2012, 76:1761-1766.
18. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Long lasting effects of sublingual immunotherapy according to its duration: a 15 year prospective study. J Allergy Clin Immunol 2010, 126:969-975.
19. Didier A., Malling H.-J., Worm M., Horak F., Sussman G., Melac M., et al. Post-treatment efficacy of discontinuous treatment with 300 IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013, 43:568-577.
20. Passalacqua G., Compalati E., Canonica G.W. Sublingual immunotherapy: other indications. Immunol Allergy Clin North Am 2011, 31:79-87.
21. Passalacqua G., Lombardi C., Troise C., Canonica G.W. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur Ann Allergy Clin Immunol 2009, 41:163-170.
22. Fleischer D.M., Burks W.A., Vickery B.P., Scurlock A.M., Wood R.A., Jones S.M., et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013, 131:119-127.
23. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(suppl):S1-55.
24. Cox L., Casale T.B., Nayak A.S., Bernstein D.I., Creticos P.S., Ambroisine L., et al. Clinical efficacy of 300 IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012, 130:1327-1334.
25. Park D., Daher N., Blaiss M.S. Adult and pediatric clinical trials of sublingual immunotherapy in the USA. Expert Rev Clin Immunol 2012, 8:557-564.
26. Sikora J.M., Tankersley M.S. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. Ann Allergy Asthma Immunol 2013, 110:194-197.
27. Novak N., Haberstok J., Bieber T., Allam J.P. The immune privilege of the oral mucosa. Trends Mol Med 2008, 14:191-198.
28. Mascarell L., Lombardi V., Zimmer A., Louise A., Tourdot S., Van Overtvelt L., et al. Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells. Clin Exp Allergy 2009, 39:1910-1919.
29. Allam J.P., Duan Y., Winter J., Stojanovski G., Fronhoffs F., Wenghoefer M., et al. Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites. Allergy 2011, 66:532-539.
30. + T cells. J Allergy Clin Immunol 2008, 122:603-609.
31. Allam J.P., Novak N., Fuchs C., Asen S., Berge S., Appel T., et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans cell type with high constitutive FcεRI expression. J Allergy Clin Immunol 2003, 112:141-148.
32. Mascarell L., Saint-Lu N., Moussu H., Zimmer A., Louise A., Lone Y., et al. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol 2011, 4:638-647.
33. Razafindratsita A., Saint-Lu N., Mascarell L., Berjont N., Bardon T., Betbeder D., et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007, 120:278-285.
34. Saint Lu N., Tourdot S., Razafindrasita A., Mascarell L., Berjont N., Chabre H., et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009, 64:1003-1013.
35. Allam J.P., Wurtzen P.A., Reinartz M., Winter J., Vrtala S., Chen K.W., et al. Phl p 5 resorption in human oral mucosa leads to dose dependent and time dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation and enhances their migratory and TGFβ1 and IL10 producing properties. J Allergy Clin Immunol 2010, 126:638-645.
36. Allam J.P., Peng W.M., Appel T., Wenghoefer M., Niederhagen B., Bieber T., et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008, 121:368-374.
37. Larché M. Immune mechanisms of sublingual immunotherapy: are oral Langerhans cells the masters of tolerance?. J Allergy Clin Immunol 2010, 126:646-647.
38. Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindermann M.J., et al. Th17 cells and IL17 receptor signalling are essential for mucosal host defence against oral candidiasis. J Exp Med 2009, 206:299-311.
39. Allam J.P., Stojanovski G., Friedrichs N., Peng W., Bieber T., Wenzel J., et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?. Allergy 2008, 63:720-727.
40. Marcucci F., Sensi L., Incorvaia C., Di Cara G., Cadario G., Moingeon P., et al. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy 2007, 62:1475-1477.
41. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodelling. Nature Immunol 2010, 2:21-27.
42. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells, a proposal for uniform nomenclature. Nature Rev 2013, 13:145-149.
43. Nudel I., Elnekave M., Furmanov K., Arizon K., Clausen B.E., Wilensky A., et al. Dendritic cells in distinct oral mucosal tissues engage different mechanisms to prime CD8+ T cells. J Immunol 2011, 186:891-900.
44. Amuguni J.H., Lee S., Kerstein K.O., Brown D.W., Belitsky B.R., Herrmann J.E., et al. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine 2011, 29:4778-4784.
45. Ma S., Sicherer S.H., Nowak-Wegrzyn A. A survey on the management of pollen-food allergy syndrome in allergy practice. J Allergy Clin Immunol 2003, 112:784-788.
46. Palomares O., Ruckert B., Jartti T., Kucuksezer U.C., Puhakka T., Gomez E., et al. Induction and maintenance of allergen-specific Foxp3+ T reg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol 2012, 129:510-520.
47. Stent G., Reece J.C., Baylis D.C., Ivinson K., Paukovics G., Thomson M., et al. Heterogeneity of freshly isolated human tonsil dendritic cells demonstrated by intracellular markers, phagocytosis and membrane dye transfer. Cytometry 2002, 48:167-176.
48. Polak M.E., Borthwick N.J., Gabriel F.G., Jager M.J., Cree I.A. Activation of tonsil dendritic cells with immune-adjuvants. BMC Immunol 2008, 9:1-12.
49. Kucuksezer U.C., Palomares O., Ruckert B., Jartti T., Puhakka T., Nandy A., et al. Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T cell tolerance in human tonsils and peripheral blood. J Allergy Clin Immunol 2013, 131:875-885.e9.
50. Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214.
51. Relman D.A. Learning about who we are. Nature 2012, 486:194-195.
52. Van Overtvelt L., Lombardi V., Razafindratsita A., Saint-Lu N., Horiot S., Moussu H., et al. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2008, 145:152-162.
53. Van Overtvelt L., Moussu H., Horiot S., Samson S., Lombardi V., Mascarell L., et al. Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine 2010, 28:2986-2992.
54. Moussu H., van Overtvelt L., Horiot S., Tourdot S., Airouche S., Nutten S., et al. Bifidobacterium bifidum promotes tolerance induction in murine models of sublingual immunotherapy. Int Arch Allergy Immunol 2012, 158:35-42.
55. Rawas Qalaji M.M., Simons F.E., Simons K.J. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. J Allergy Clin Immunol 2006, 117:398-403.
56. Bagnasco M., Passalacqua G., Villa G., Augeri C., Flamigni G., Borini E., et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001, 31:54-60.
57. Bagnasco M., Altrinetti V., Pesce G., Caputo M., Mistrello G., Falagliani P., et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005, 138:197-202.
58. Martin-Fotecha A., Sebastiani S., Hopken U., Uguccioni M., Lipp M., Lanzavecchia A., et al. Regulation of dendritic cell migration to the lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003, 198:615-621.
59. Gardner L.M., Spyroglou L., O'Hehir R.E., Rolland J.M. Increased allergen concentration enhances IFN-gamma production by allergic donor T cells expressing a peripheral tissue trafficking phenotype. Allergy 2004, 59:1308-1317.
60. Strickland D.H., Stumbles P.A., Zosky G.R., Subrata L.S., Thomas J.A., Turner D.J., et al. Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells. J Exp Med 2006, 203:2649-2660.
61. Meiler F., Zumkehr J., Klunker S., Ruckert B., Akdis C., Akdis M. In vivo switch to IL10 secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008, 205:2887-2898.
62. Gidaro G.B., Marcucci F., Sensi L., Incorvaia C., Frati F., Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005, 35:565-571.
63. Calderon M.A., Simons F.E., Malling H.J., Lockey R.F., Moingeon P., Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012, 67:302-311.
64. Bernstein D.I., Epstein T., Murphy-Berendts K., Liss G.M. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010, 104:530-535.
65. Rossi R., Monasterolo G., Incorvaia C., Moingeon P., Frati F., Passalacqua G., et al. Lack of neo sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy. Clin Mol Allergy 2010, 8:4-11.
66. Baron-Bodo V., Batard T., Nguyen H., Fréreux M., Horiot S., Harwanegg K.C., et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy 2012, 42:1510-1518.
67. Cosmi L., Santarlasci V., Angeli R., Liotta F., Maggi L., Frosali F., et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-γ- and interleukin-10-production. Clin Exp Allergy 2006, 36:261-272.
68. Bohle B., Kinaciyan T., Gerstmayr M., Radakovics A., Jahn-Schmid B., Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007, 120:707-713.
69. Ciprandi G., De Amici M., Marseglia G.L. Serum IL9 levels and sublingual immunotherapy: preliminary report. J Biol Regul Homeost Agents 2011, 25:295-297.
70. Ciprandi G., Fenoglio D., Cirillo I., Vizzaccaro A., Ferrera A., Tosca M.A., et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005, 95:38-44.
71. Savolainen J., Jacobsen L., Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006, 61:1184-1190.
72. Eifan A.O., Akkoc T., Yildiz A., Keles S., Ozdemir C., Bahceciler N.N., et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010, 40:922-932.
73. Fujimura T., Yonekura S., Taniguchi Y., Horiguchi S., Saito A., Yasueda H., et al. The induced regulatory T Cell level, defined as the proportion of IL-10+ Foxp3+ cells among CD25+ CD4+ leukocytes, is a potential therapeutic biomarker for sublingual immunotherapy: a preliminary report. Int Arch Allergy Immunol 2010, 153:378-387.
74. Fujimura T., Yonekura S., Horiguchi S., Taniguchi Y., Saito A., Yasueda H., et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis. Clin Immunol 2011, 139:65-74.
75. Swamy R.S., Reshamwala N., Hunter T., Vissamsetti S., Santos C.B., Baroody F.M., et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol 2012, 130:215-224.
76. + regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand J Immunol 2006, 64:251-259.
77. Sun J.B., Flach C.F., Czerkinsky C., Holmgren J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J Immunol 2008, 181:8278-8287.
78. O'Hehir R.E., Gardner L.M., de Leon M.P., Hales B.J., Biondo M., Douglass J.A., et al. House dust mite sublingual immunotherapy. The role for transforming growth factor B and functional regulatory T cells. Am J Resp Crit Care Med 2009, 180:936-947.
79. Pilette C., Nouri-Aria K.T., Jacobson M.R., Wilcock L.K., Detry B., Walker S.M., et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007, 178:4658-4666.
80. Rolinck-Werninghaus C.K., Liebke C., Lange J., Wahn U., Niggerman B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005, 136:134-141.
81. Piconi S., Trabattoni D., Rainone V., Borgnonovo L., Passerini S., Rizzardini G., et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. J. Immunol 2010, 185:7723-7730.
82. Dehlink E., Eiwegger T., Gerstmayr M., Kampl E., Bohle B., Chen K.W., et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006, 36:32-39.
83. Bonvalet M., Moussu H., Wambre E., Ricarte C., Horiot S., Rimaniol A.C., et al. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy. Clin Exp Allergy 2012, 42:1745-1755.
84. Scadding G.W., Shamji M.H., Jacobson M.R., Lee D.I., Wilson D., Lima M.T., et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010, 40:598-606.
85. Bahceciler N.N., Arikan C., Taylor A., Akdis M., Blaser K., Barlan I.B., et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005, 136:287-294.
86. James L.K., Shamji M.H., Walker S.M., Wilson D.R., Wachholz P.A., Francis J.N., et al. Long term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011, 127:509-516.
87. Shamji M.H., Ljorring C., Francis J.N., Calderon M.A., Larche M., Kimber I., et al. Functional rather that immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012, 67:217-226.
88. James L.K., Bowen H., Calvert R.A., Dodev T.S., Shamji M.H., Beavil A.J., et al. Allergen specificity of IgG4-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol 2012, 130:663-670.e3.
89. Kaminuma O., Suzuki K., Mori A. Effect of sublingual immunotherapy on antigen induced bronchial and nasal inflammation in mice. Int Arch Allergy Immunol 2010, 152:75-78.
90. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005, 115:1184-1188.
91. Angelini F., Pacciani V., Corrente S., Silenzi R., Di Pede A., Polito A., et al. Dendritic cells modification during sublingual immunotherapy in children with allergic symptoms to house dust mites. World J Pediatr 2011, 7:24-30.
92. Zimmer A., Bouley J., Le Mignon M., Pliquet E., Horiot S., Turfkruger M., et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen immunotherapy. J. Allergy Clin Immunol 2012, 129:1020-1030.
93. Passalacqua G., Albano M., Riccio A., Fregonese L., Puccinelli P., Parmiani S., et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999, 104:964-968.
94. Horak F., Zieglmayer P., Lemell P., Devillier P., Montagut A., Melac M., et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009, 124:471-477.
95. Michils A., Baldassare S., Ledent C., Mairesse M., Gossart B., Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy 2000, 55:455-462.
96. Bussmann C., Xia J., Allam J.P., Maintz L., Bieber T., Novak N. Early markers for protective mechanisms during rush venom immunotherapy. Exp Allergy Immunol 2010, 65:1558-1565.
97. Van Overtvelt L., Baron-Bodo V., Horiot S., Moussu H., Ricarte C., Horak F., et al. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy 2011, 66:1530-1537.
98. Wambre E., DeLong J.H., James E.A., Lafond R.E., Robinson D., Kwok W.W., et al. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012, 129:544-551.
99. Di Lorenzo G., Mansueto P., Pacor M.L., Rizzo M., Castello F., Martinelli N., et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009, 123:1103-1110.
100. Francis J.N., James L.K., Paraskevopoulos G., Wong C., Calderon M.A., Durham S.R., et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008, 121:1120-1125.
101. Moingeon P. Sublingual immunotherapy: from biological extracts to recombinant allergens. Allergy 2006, 61:15-19.
102. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002, 2:446-453.
103. Himly M., Nony E., Chabre H., Van Overtvelt L., Neubauer A., Van Ree R., et al. Standardization of allergen products: detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation. Allergy 2009, 64:1038-1045.
104. Moingeon P. Adjuvants for allergy vaccines. Hum Vaccines Immunother 2012, 8:1-7.
105. Lombardi V., Van Overtvelt L., Horiot S., Moussu H., Chabre H., Louise A., et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008, 38:1819-1829.
106. Mascarell L., Van Overtvelt L., Lombardi L., Razafindratsita, Moussu H., Horiot S., et al. A synthetic triacylated pseudodipeptide molecule promotes Th1/T Reg immune responses and enhances tolerance induction via the sublingual route. Vaccine 2007, 26:108-118.
107. Pfaar O., Barth C., Jaschke C., Hörmann K., Klimek L. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2010, 154:336-344.
108. Arikan C., Bahceciler N.N., Deniz G., Akdis M., Akkoc T., Akdis C.A., et al. Bacillus Calmette-Guérin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004, 34:398-405.
109. Batard T., Zimmer A., Nony E., Bouley J., Airouche S., Luce S., et al. Anti-inflammatory activity of sublingual immunoglobulin (SLIG) in a murine model of allergen-driven airway inflammation. Vaccine 2012, 30:5666-5674.
110. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011, 127:315-323.
111. Van Ree R., Antonicelli L., Akkerdaas J.H., Garritani M.S., Aalberse R.C., Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy 1996, 51:108-113.
112. Fujihashi K., Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol 2009, 30:334-343.
113. Linneberg A., Madsen F., Skaaby T. Allergen specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol 2012, 12:635-639.
114. Shaikh W.A., Skaik S.W. A prospective study on the safety of sublingual immunotherapy in pregnancy. Allergy 2012, 67:741-743.
115. Zuberbier T., Bachert C., Bousquet P.J., Passalacqua G., Canonica W.G., Merk H., et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010, 65:1525-1530.
116. Nelson H.S. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009, 123:763-769.
117. Calderon M.A., Cox L., Casale T.B., Moingeon P., Demoly P. Multiple allergen and single allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012, 129:929-934.
118. Migueres M., Fontaine J.F., Haddad T., Grosclaude M., Saint-Martin F., Bem-David D., et al. Characteristics of patients with respiratory in France and factors influencing immunotherapy prescription: a prospective observational study (Realis). Int J Immunol Pharmacol 2011, 24:387-400.
119. Malling H.J., Montagut A., Melac M., Patriarca G., Panzner P. Seberova. Efficacy and safety of 5 grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy 2009, 39:387-393.
120. Nelson H., Blaiss M., Nolte H., Wurtz S.O., Adersen J.S., Durham S.R. Efficacy and safety of the SQ standardized grass allergy immunotherapy tablet in mono and polysensitized subjects. Allergy 2013, 68:252-255.
121. Ciprandi G., Incorvaia C., Pulcinelli P., Scurati S., Masieri S., Frati F. The POLISMAIL lesson: sublingual immunotherapy may be prescribed also in polysensitized patients. Int J Immunopathol Pharmacol 2010, 23:637-640.
122. Lee J.E., Choi Y.S., Kim M.S., Han D.H., Rhee C.S., Lee C.H., et al. Efficacy of SLIT with HDM extract in polyallergen sensitized patients with allergic rhinitis. Ann Allergy Asthma Immunol 2011, 107:79-84.
123. Marogna M., Spadolini I., Massolo A., Zanon P., Berra D., Chiodini I., et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol 2007, 98:274-280.
124. Bar-On E.S., Goldberg E., Fraser A., Vidal L., Hellmann S., Leibovici L. Combined DTP-HBV-HiB vaccine versus separately administered DTP-HBV and HiB vaccines for primary prevention of diphteria, tetanus, pertussis, hepatitis B and Haemophilus influenza B. Cochrane Database Syst Rev 2009, (3):CD005530.
125. Amar S.M., Harbeck R.J., Sills M., Silveira L.J., O'Brien H., Nelson H.S. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009, 124:150-156.